Compare MPLX LP (MPLX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Novo Nordisk A/S — how do they compare? MPLX LP trades at $59.9 (market cap $60.12B), while Novo Nordisk A/S trades at $46.49 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 3.5× MPLX LP's market cap, and MPLX LP pays the higher dividend (7.26%). Which is the better fit depends on your goals.
| MPLX | NVO | |
|---|---|---|
Market Cap | $60.12B | $207.85B |
Sector | Technology | Health |
52-Week High | $60.51 | $63.98 |
52-Week Low | $47.80 | $35.29 |
Enterprise Value | $85.22B | $222.55B |
Dividend Yield | 7.26% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $59.94, up 2.11% today, with a bullish technical signal from moving averages and a consensus analyst price target of $61.50. The company reported strong 2025 results with $11.47B revenue and $4.91B net income, though recent quarterly earnings have missed expectations. A recent $2.25B senior notes offering (PRNewsWire, Aug 10, 2026) supports growth initiatives, while a 7.3% dividend yield attracts income investors.
Outlook remains positive given fee-based revenue stability and growth projects, but risks include execution challenges from higher capital spending and leverage. Analyst sentiment is strongly bullish with no sell ratings, though investors should monitor earnings consistency and debt levels amid volatile energy markets.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
